Xeris Biopharma Holdings (XERS) Equity Ratio (2020 - 2026)

Xeris Biopharma Holdings has reported Equity Ratio for 7 years, with the latest figure at 0.03 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 129.81% year-over-year to 0.03; the trailing twelve-month figure through Mar 2026 stood at 0.03 (up 129.81% YoY), and the FY2025 full-year result was 0.04, up 138.94% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.03, down from 0.04 in the prior quarter.
• The five-year high for Equity Ratio was 0.29 in Q1 2022, with the low at 0.11 in Q1 2025.
• Historically, Equity Ratio has averaged 0.03 across 5 years, with a median of 0.01 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio jumped 1068.8% — and 2024, when it tumbled 848.05%.
• Xeris Biopharma Holdings' Equity Ratio stood at 0.13 in 2022, then slumped by 116.03% to 0.02 in 2023, then sank by 336.05% to 0.09 in 2024, then soared by 138.94% to 0.04 in 2025, then decreased by 7.01% to 0.03 in 2026.
• The last three Equity Ratio figures came in at 0.03 (Q1 2026), 0.04 (Q4 2025), and 0.0 (Q3 2025), per Business Quant data.